Expand AMLX Menu
AMLX MENU

AMLX Latest Press Releases

-- January 8, 2026 --

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S Business Wire 7:00 AM

-- December 5, 2025 --

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial Business Wire 9:00 AM

-- November 28, 2025 --

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS PRNewswire 6:40 PM

-- November 11, 2025 --

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. - AMLX Business Wire 6:00 PM

-- November 6, 2025 --

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf Globe Newswire 10:28 AM
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results Business Wire 7:00 AM

-- November 3, 2025 --

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire 9:00 AM

-- October 30, 2025 --

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf Globe Newswire 9:20 AM
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 Business Wire 9:00 AM

-- October 27, 2025 --

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights Business Wire 12:20 PM

-- October 23, 2025 --

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf Globe Newswire 7:38 AM

-- October 22, 2025 --

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm PRNewswire 10:13 AM

-- October 20, 2025 --

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 7:49 AM

-- October 17, 2025 --

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 8:35 AM

-- October 16, 2025 --

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders Globe Newswire 4:40 PM

-- October 13, 2025 --

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 8:43 AM

-- October 10, 2025 --

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm Globe Newswire 10:36 AM

-- October 9, 2025 --

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 9:38 AM

-- October 8, 2025 --

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 8:44 AM

-- October 6, 2025 --

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm PRNewswire 12:25 PM

-- September 10, 2025 --

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock Business Wire 12:06 AM

-- September 9, 2025 --

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire 4:01 PM

-- August 27, 2025 --

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) Business Wire 7:00 AM

-- August 26, 2025 --

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 9:00 AM
Market Data Delayed 15 Minutes